T2 Biosystems, Inc. (0A57.L)
| Chiusura precedente | 0,1505 |
| Aperto | 0,1409 |
| Denaro | 0,0000 x N/D |
| Lettera | 0,0000 x N/D |
| Min-Max giorno | 0,1363 - 0,1409 |
| Intervallo di 52 settimane | 0,1363 - 0,1409 |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | 0,46 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,3350 |
| Prossima data utili | 02 nov 2022 - 07 nov 2022 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
T2 Biosystems to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase
LEXINGTON, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to present at the upcoming Inaugural Gilmartin Group Emerging Growth Company Showcase, taking place virtually. Members of management are scheduled to present on Wednesday, August 31, 2022, at 11:30am ET. Interested parties can access a live webcast of the presentation directly by following this li
- GlobeNewswire
T2 Biosystems Announces Second Quarter 2022 Financial Results
T2Dx Instrument contracts increased by 300% compared to the prior year periodLEXINGTON, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced financial results for the second quarter ended June 30, 2022. Recent Highlights Achieved second quarter total revenue of $5.9 million, including product revenue of $2.6 million, representing decreases of 12% and
- GlobeNewswire
T2 Biosystems to Explore Potential to Develop Rapid Molecular Diagnostic Test for Monkeypox Virus
LEXINGTON, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today plans to explore the potential to develop a rapid molecular diagnostic test for detection of the monkeypox virus, including technical and commercial feasibility. Monkeypox is a rare disease caused by infection with the monkeypox virus that is part of the orthopoxvirus family of viruses, which also contai
